Has Kamlesh Pandya, MD received payments from drug or device companies?

Yes. Drug and device makers reported $9,485 in general payments to Kamlesh Pandya, MD across 50 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kamlesh Pandya, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kamlesh Pandya, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kamlesh Pandya, MD

Pulmonary Disease · Fort Pierce, FLNPI 1750440020

Payments from drug & device makers

$9,485in general payments, 2019–2025

Across 50 payments — averaging $189.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim$6K
Edwards Lifesciences$1K
Olympus Corporation Of The Americas$871
Medical Device Business Services, Inc.$365
AstraZeneca$347
United Therapeutics Corporation$263
plus $843 from 9 others

What the payments were for

Speaking & faculty fees$5,53558%
Travel & lodging$1,97021%
Food & beverage$1,92220%
Education$581%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim	5	$5,676
Edwards Lifesciences	9	$1,119
Olympus Corporation Of The Americas	8	$871
Medical Device Business Services, Inc.	7	$365
AstraZeneca	4	$347
United Therapeutics Corporation	3	$263
Boston Scientific	2	$260
Johnson & Johnson	4	$250
Merck	2	$131
Mallinckrodt Enterprises LLC	1	$72
Genentech USA, Inc.	1	$40
Harmony Biosciences LLC	1	$34
GSK	1	$24
Mylan Specialty L.p.	1	$19
Pfizer	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,485 in reported general payments places this provider in the 65th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida →

Medicare billing

Part B allowed, 2024

$114,899

Medicare patients

250

Services billed

989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Fort Pierce

James KrainsonMiami$11.7M
Jose DiazLeesburg$11.2M
Carlos MartinezHomestead$9.2M
Leonard DunnDunedin$7.6M
Francis AverillClearwater$6.3M
Charles BurgerJacksonville$5.6M
Daniel LorchBrandon$5.5M
Lourdes BoschMiami$4.2M
Raj KarunakaraOcala$4M
Neal WarshoffLoxahatchee$3.6M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →